Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
OBJECTIVE: To examine initiation of newer antiretroviral treatments across sociodemographic subgroups during the 3 years following the introduction of these treatments, and explore persistence on treatment and its association with patient characteristics.
DESIGN: Merged Medicaid paid claims and HIV/AIDS surveillance data were used to analyze use of protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) over time. Survival analysis techniques were used to analyze initiation of PI/NNRTI use. Ordinary least squares and logistic regression were used to determine predictors of persistence on PI/NNRTI therapy.
SETTING AND PARTICIPANTS: The study population consisted of 2,459 New Jersey non-HMO adult Medicaid beneficiaries with AIDS, identified through a match between HIV/AIDS Registry and Medicaid files. Their PI/NNRTI use was followed from March 1996, when the first PI was licensed, to the end of 1998.
MEASUREMENTS AND MAIN RESULTS: African Americans initiated treatment on average 8 months later than non-Hispanic whites; initiation of treatment was also slower for injection drug users and for those who did not receive case management through a Medicaid waiver program. These bivariate findings were confirmed with a multivariate time-to-treatment analysis using proportional hazards regression. Among those initiating PI/NNRTI use, 35% had discontinued it by the end of follow-up. Bivariate analyses of treated individuals found that PI/NNRTI use as a proportion of follow-up time was lower for African Americans and Hispanics, and higher for older individuals and for those receiving case management through a Medicaid waiver program, while injection drug use history was not associated with persistence. These findings were confirmed by a regression analysis, which found that controlling for other characteristics, African-American race, and Hispanic ethnicity were each associated with a significant 8% reduction in the proportion of time on PI/NNRTIs following initiation of treatment. Alternative approaches for modeling persistence produced similar results.
CONCLUSIONS: Results suggest that consistent longitudinal use is difficult for many patients. Persistence of use was lower for minority beneficiaries despite comparable coverage for pharmacy and other health services through Medicaid. Our findings suggest the need to examine nonfinancial barriers to appropriate use of highly active antiretroviral therapy, and to develop and test programmatic strategies for supporting patients in remaining on these regimens consistently.
- Hogg, RS, Heath, KV, Yip, B (1998) Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 279: pp. 450-4 CrossRef
- Palella, J, Frank, J, Delaney, KM (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338: pp. 853-60 CrossRef
- Carpenter, CCJ, Fischl, MA, Hammer, SM (1997) Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society, USA panel. JAMA 277: pp. 1962-9 CrossRef
- Deeks, SG, Smith, M, Holodniy, M, Kahn, JO (1997) HIV-1 protease inhibitors: a review for clinicians. JAMA 277: pp. 145-53 CrossRef
- Fauci, AS (1996) AIDS in 1996: much accomplished, much to do. JAMA 276: pp. 155-6 CrossRef
- Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Morb Mortal Wkly Rep 47: pp. 43-82
- Bonfanti, P, Capetti, A, Rizzardini, G (1999) HIV disease treatment in the era of HAART. Biomed Pharmacother 53: pp. 93-105 CrossRef
- Lucas, GM, Chaisson, RE, Moore, RD (1999) Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 131: pp. 81-7
- Erice, A, Mayers, DL, Strike, DG (1993) Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 328: pp. 1163-5 CrossRef
- Hecht, FM, Grant, RM, Petropoulos, CJ (1998) Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 339: pp. 307-11 CrossRef
- Boden, D, Hurley, A, Zhang, L (1999) HIV-1 drug resistance in newly infected individuals. JAMA 282: pp. 1135-41 CrossRef
- Shapiro, MF, Morton, SC, McCaffrey, DF (1999) Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA 281: pp. 2305-15 CrossRef
- Bing, EG, Kilbourne, AM, Brooks, RA, Lazarus, EF, Senak, M (1999) Protease inhibitor use among a community sample of people with HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 20: pp. 474-80
- Sorvillo, F, Kerndt, P, Odem, S (1999) Use of protease inhibitors among persons with AIDS in Los Angeles County. AIDS Care 11: pp. 147-55 CrossRef
- Sackoff, JE, McFarland, JW, Shin, SS (2000) Trends in prescriptions for highly active antiretroviral therapy in four New York City HIV clinics. J AIDS 23: pp. 178-83
- Mehta, S, Moore, RD, Graham, NMH (1997) Potential factors affecting adherence with HIV therapy. AIDS 11: pp. 1665-70 CrossRef
- Bangsberg, D, Tulsky, JP, Hecht, FM, Moss, AR (1997) Protease inhibitors in the homeless. JAMA 278: pp. 63-5 CrossRef
- Bayer, R, Stryker, J (1997) Ethical challenges posed by clinical progress in AIDS. Am J Public Health 87: pp. 1599-602
- Roon, EN, Verzijl, JM, Juttmann, JR, Lenderink, AW, Blans, MJ, Egberts, AC (1999) Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol 20: pp. 290-4
- Malow, RM, McPherson, S, Kilmas, N (1998) Adherence to complex combination antiretroviral therapies by HIV-positive drug abusers. Alcohol Drug Abuse 49: pp. 1021-4
- Kalichman, SC, Ramachandran, B, Catz, S (1999) Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med 14: pp. 267-73 CrossRef
- Gordillo, V, Amo, J, Soriano, V, Gonzalez-Lahoz, J (1999) Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 13: pp. 1763-9 CrossRef
- Catz, SL, Kelly, JA, Bogart, LM, Benotsch, EG, McAuliffe, TL (2000) Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 19: pp. 124-33 CrossRef
- Bassetti, S, Battegay, M, Furrer, H (1999) Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued?. J AIDS 21: pp. 114-9
- Eldred, LJ, Wu, AW, Chaisson, RE, Moore, RD (1998) Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J AIDS 18: pp. 117-225
- Kastrissios, H, Suarez, JR, Hammer, S, Katzenstein, D, Blaschke, TF (1998) The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker. AIDS 12: pp. 2305-11 CrossRef
- Haubrich, RH, Little, SJ, Currier, JS (1999) The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 13: pp. 1099-107 CrossRef
- Rigsby, MO, Rosen, MI, Beauvais, JE (2000) Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med 15: pp. 841-7 CrossRef
- Laine, C, Newschaffer, CJ, Zhang, D, Cosler, L, Hauck, WW, Turner, BJ (2000) Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol 95: pp. 167-73 CrossRef
- Crystal, S, Sambamoorthi, U, Merzel, C (1995) The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts. Health Serv Res 30: pp. 593-614
- Broers, B, Morabia, A, Hirschel, B (1994) A cohort study of drug users’ compliance with zidovudine treatment. Arch Intern Med 154: pp. 1121-7 CrossRef
- Center for Medicaid and State Operations. Medicaid and acquired immune deficiency syndrome (AIDS) and human immunodeficiency virus (HIV) infection. http://www.hcfa.gov/medicaid/obs11.htm. April 2000.
- Berk, ML, Schur, CL (1998) Access to care: how much difference does Medicaid make?. Health Aff (Millwood) 17: pp. 169-80 CrossRef
- Henry, K (2000) The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med 132: pp. 306-11
- Regenstein M, Anthony SE. Medicaid managed care for persons with disabilities. Economic and Social Research Institute. August 1998. http://newfederalism.urban.org/html/occa11.html#medi.
- Turner, BJ, Newschaffer, CJ, Zhang, D (2000) Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care 38: pp. 911-25 CrossRef
- Fasciano, NJ, Cherlow, AL, Turner, BJ, Thornton, CV (1998) Profile of Medicare beneficiaries with AIDS: application of an AIDS case-finding algorithm. Health Care Financ Rev 19: pp. 19-38
- Sambamoorthi U, Collins S, Crystal S. Characteristics of dually-eligible Medicaid beneficiaries. J Health Soc Policy. In press.
- Merzel, C, Crystal, S, Sambamoorthi, U, Karus, D, Kurland, C (1992) New Jersey’s Medicaid waiver for acquired immunodeficiency syndrome. Health Care Financ Rev 13: pp. 27-44
- Diggle, P, Liang, KY, Zeger, S (1994) Analysis of Longitudinal Data. Oxford University Press, Oxford and New York
- Kalbfleisch, JD, Prentice, RL (1980) The Statistical Analysis of Failure Time Data. John Wiley and Sons, Inc., New York
- Aday, LA, Anderson, RM (1984) The national profile of access to medical care: where do we stand?. Am J Public Health 74: pp. 1331-9
- Bindman, AB, Grumbach, K, Osmond, D (1995) Preventable hospitalizations and access in health care. JAMA 274: pp. 305-11 CrossRef
- Peterson, ED, Wright, SM, Daley, J, Thibault, GE (1994) Racial variation in cardiac procedure use and survival following acute myocardial infarction in the department of veterans affairs. JAMA 271: pp. 1175-80 CrossRef
- Whittle, J, Conigliaro, J, Good, CB, Joswiak, M (1993) Racial differences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs medical system. N Engl J Med 329: pp. 621-7 CrossRef
- Carlisle, DM, Leake, BD, Shapiro, MF (1997) Racial and ethnic disparities in the use of cardiovascular procedures: associations with types of health insurance. Am J Public Health 87: pp. 263-7 CrossRef
- Gornick, ME, Eggers, PW, Reilly, TW (1996) Effects of race and income on mortality and use of services among Medicare beneficiaries. N Engl J Med 335: pp. 791-9 CrossRef
- Satariano, ER, Swanson, GM, Moll, PP (1992) Nonclinical factors associated with surgery received for treatment of early stage breast cancer. Am J Public Health 82: pp. 195-8
- Diehr, P, Yergan, J, Chu, J (1995) The influence of race on the use of surgical procedures for treatment of peripheral vascular disease of the lower extremities. Arch Surg 130: pp. 381-6
- Center for Disease Control. Fighting HIV/AIDS in African American communities: a growing crisis. http://www.cdc.gov/hiv/pubs/brochure/African-American.pdf; October 4, 2000.
- Fairfield, KM, Libman, H, Davis, RB, Eisenberg, DM, Phillips, RS (1999) Delays in protease inhibitor use in clinical practice. J Gen Intern Med 14: pp. 395-401 CrossRef
- Kitahata, MM, Koepseli, TD, Deyo, RA, Maxwell, CL, Dodge, WT, Wagner, EH (1996) Physicians’ experience with the acquired immunodeficiency syndrome as a factor in patients’ survival. N Engl J Med 334: pp. 701-6 CrossRef
- Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral adherence. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 1999. Abstract 98.
- AIDS among people aged 50 or older years—U.S., 1991–1996. JAMA 279: pp. 576-576 CrossRef
- Anderson, K, Mitchell, JM (1997) Expenditures on services for persons with acquired immunodeficiency syndrome under a medicaid home- and community-based waiver program: are selection effects important?. Med Care 35: pp. 425-39 CrossRef
- Division of AIDS Prevention and Control begins broad initiative to decrease perinatal transmission. AIDSline 11: pp. 1-2
- Hakki M, Cinti SK. Gaps in pharmacy logs predict poor virologic outcome in HIV-infected patients on highly active antiretroviral therapy. Presented at the annual meeting of the Michigan Infectious Disease Society, Lansing, Mich, March 2000.
- Singh, N, Berman, SM, Swindells, S (1999) Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 29: pp. 824-30
- Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS
Journal of General Internal Medicine
Volume 16, Issue 12 , pp 850-859
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- protease inhibitors
- Industry Sectors